JDRF commits $5m to carry diabetes therapies through "valley of
16 October 2013
JDRF, the world's largest charity funding type 1 diabetes
research, and technology development company PureTech, have launched
T1D Innovations, an organisation focussed on accelerating the
development of innovative diabetes therapies.
T1D Innovations will create and fund high-impact companies
developing innovative type 1 diabetes-related therapies, enabling
them to cross the well-known biomedical "valley of death" — the
notorious gap in funding opportunities that often prevents promising
biomedical discoveries from being translated into patient-saving
In addition to JDRF's leadership role in this initiative, Special
Partners Joslin Diabetes Center and T1D Exchange will bring their
valuable scientific, clinical, and patient engagement capabilities
to the collaboration.
T1D Innovations was spawned from PureTech's broader "Valley of
Life" initiative, which is designed to commercialize breakthroughs
in areas of great unmet medical need by bringing together interested
companies, disease foundations, and investors.
At a time when basic biomedical innovation is flourishing but
translational funding is scarce, JDRF and PureTech believe
collaborative translational and entrepreneurial efforts such as this
will be critical to bolstering the type 1 diabetes product pipeline
and accelerating the development of groundbreaking products.
PureTech will combine JDRF's investment with those from other
leading not-for-profit, strategic, and financial investors to create
a resource pool with the potential to have a meaningful impact on
the T1D product pipeline. Additional investors will be required to
achieve the objectives of this initiative and investors will also
participate in any financial returns.
T1D Innovations will enable and accelerate the development and
progress of opportunities aligned with JDRF's research priorities,
placing an emphasis on therapies that help restore or maintain
glycemic control or have the potential of restoring normal
physiology for people living with or at risk for developing T1D.
JDRF's funding of T1D Innovations represents a multi-year commitment
to this effort.
JDRF President and CEO Jeffrey Brewer said, "T1D Innovations is a
unique opportunity to fund entrepreneurial activity at the
translational stage of the type 1 diabetes product pipeline,
allowing us to drive the most commercially promising type 1 diabetes
research projects into the clinic while leveraging the co-investment
of other partners.
"This new initiative complements JDRF's current grant making and
industry partnering activities, which are respectively focused on
early stage exploratory research and later stage product development
opportunities. Now, by supporting company formation around
breakthrough type 1 diabetes research and working at each phase of
the R&D pipeline, JDRF is better positioned to achieve our goal of
delivering progressively advanced therapies to individuals living
with or at risk of type 1 diabetes."